BCMA-CD19 cCAR T

BCMA-CD19 chimeric antigen receptor T-cell therapy · iCell Gene Therapeutics

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for BCMA-CD19 cCAR T, covering 2026-01-09 to 2026-04-22. Get the full timeline:

Most recent: Clinical Trial Update: BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD) [Phase 1, Phase 2]